Drugs / Fecal microbiota transfer
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05690048 | Jul 2025 → Mar 2028 expected | hepatocellular carcinoma | Michael Dill | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fecal microbiota transfer | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05690048 ↗ |
| Known as | INTESTIFIX 001 | “INTESTIFIX 001 is an encapsulated FMT preparation by healthy donors with a high alpha-diversity in their gut microbiome for oral administration, manufactured by the Cologne...” PMID 40930564 ↗ Sep 2025 |
| Modality | Other / unclassified | “INTESTIFIX 001 is an encapsulated FMT preparation by healthy donors with a high alpha-diversity in their gut microbiome for oral administration, manufactured by the Cologne...” PMID 40930564 ↗ Sep 2025 |
| Route | Oral | “INTESTIFIX 001 is an encapsulated FMT preparation by healthy donors with a high alpha-diversity in their gut microbiome for oral administration, manufactured by the Cologne...” PMID 40930564 ↗ Sep 2025 |